How to interpret differing cerebral blood flow patterns estimated with 99tcm-hmpao and 99tcm-ecd spet in a healthy population
(1999) In Nuclear Medicine Communications 20(3). p.219-226- Abstract
Two radiopharmaceuticals, 99Tcm-hexamethyl propylene amine oxime (99Tcm-HMPAO) and 99Tcm-ethyl cysteinate dimer (99Tcm-ECD), are currently used to determine cerebral blood flow. 99Tcm-ECD is, by virtue of its greater stability, superceding 99Tcm-HMPAO for routine examinations. Since the clinical assessment of 99Tcm-ECD images is usually based on experience with 99Tcm-HMPAO, we used both radiopharmaceuticals to compare regional cerebral blood flow in the same individuals. Eleven healthy subjects aged 67.1 ± 6.3 years (mean ± S.D.) underwent... (More)
Two radiopharmaceuticals, 99Tcm-hexamethyl propylene amine oxime (99Tcm-HMPAO) and 99Tcm-ethyl cysteinate dimer (99Tcm-ECD), are currently used to determine cerebral blood flow. 99Tcm-ECD is, by virtue of its greater stability, superceding 99Tcm-HMPAO for routine examinations. Since the clinical assessment of 99Tcm-ECD images is usually based on experience with 99Tcm-HMPAO, we used both radiopharmaceuticals to compare regional cerebral blood flow in the same individuals. Eleven healthy subjects aged 67.1 ± 6.3 years (mean ± S.D.) underwent 99Tcm-ECD followed by 99Tcm-HMPAO single photon emission tomography. Cerebral blood flow was quantified in cortical and central regions of interest (basal ganglia, ventricles, white matter) in relation to cerebellar uptake. The intra-subject comparison of cerebral blood flow in the cortical areas revealed higher levels of perfusion in the posterior parietal, parieto-occipital and temporo-occipital areas using 99Tcm-ECD. In contrast to the cortical areas, cerebral blood flow in the central areas was greater using 99Tcm-HMPAO, especially in the centrum semiovale, basal ganglia, frontal white matter and frontal horns. This difference in cerebral blood flow when imaging healthy individuals with 99Tcm-ECD and 99Tcm-HMPAO should be taken into account in clinical practice when changing from one radiopharmaceutical to the other.
(Less)
- author
- Siennicki-Lantz, Arkadiusz LU ; Elmståhl, Sölve LU and Lilja, B.
- organization
- publishing date
- 1999-03
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Nuclear Medicine Communications
- volume
- 20
- issue
- 3
- pages
- 219 - 226
- publisher
- Lippincott Williams & Wilkins
- external identifiers
-
- pmid:10093071
- scopus:0032909737
- ISSN
- 0143-3636
- DOI
- 10.1097/00006231-199903000-00004
- language
- English
- LU publication?
- yes
- id
- bf3c7fd6-e370-4220-9db6-1c0d758bcc3c
- date added to LUP
- 2019-06-19 11:03:55
- date last changed
- 2024-04-16 11:58:09
@article{bf3c7fd6-e370-4220-9db6-1c0d758bcc3c, abstract = {{<p>Two radiopharmaceuticals, <sup>99</sup>Tc<sup>m</sup>-hexamethyl propylene amine oxime (<sup>99</sup>Tc<sup>m</sup>-HMPAO) and <sup>99</sup>Tc<sup>m</sup>-ethyl cysteinate dimer (<sup>99</sup>Tc<sup>m</sup>-ECD), are currently used to determine cerebral blood flow. <sup>99</sup>Tc<sup>m</sup>-ECD is, by virtue of its greater stability, superceding <sup>99</sup>Tc<sup>m</sup>-HMPAO for routine examinations. Since the clinical assessment of <sup>99</sup>Tc<sup>m</sup>-ECD images is usually based on experience with <sup>99</sup>Tc<sup>m</sup>-HMPAO, we used both radiopharmaceuticals to compare regional cerebral blood flow in the same individuals. Eleven healthy subjects aged 67.1 ± 6.3 years (mean ± S.D.) underwent <sup>99</sup>Tc<sup>m</sup>-ECD followed by <sup>99</sup>Tc<sup>m</sup>-HMPAO single photon emission tomography. Cerebral blood flow was quantified in cortical and central regions of interest (basal ganglia, ventricles, white matter) in relation to cerebellar uptake. The intra-subject comparison of cerebral blood flow in the cortical areas revealed higher levels of perfusion in the posterior parietal, parieto-occipital and temporo-occipital areas using <sup>99</sup>Tc<sup>m</sup>-ECD. In contrast to the cortical areas, cerebral blood flow in the central areas was greater using <sup>99</sup>Tc<sup>m</sup>-HMPAO, especially in the centrum semiovale, basal ganglia, frontal white matter and frontal horns. This difference in cerebral blood flow when imaging healthy individuals with <sup>99</sup>Tc<sup>m</sup>-ECD and <sup>99</sup>Tc<sup>m</sup>-HMPAO should be taken into account in clinical practice when changing from one radiopharmaceutical to the other.</p>}}, author = {{Siennicki-Lantz, Arkadiusz and Elmståhl, Sölve and Lilja, B.}}, issn = {{0143-3636}}, language = {{eng}}, number = {{3}}, pages = {{219--226}}, publisher = {{Lippincott Williams & Wilkins}}, series = {{Nuclear Medicine Communications}}, title = {{How to interpret differing cerebral blood flow patterns estimated with <sup>99</sup>tc<sup>m</sup>-hmpao and <sup>99</sup>tc<sup>m</sup>-ecd spet in a healthy population}}, url = {{http://dx.doi.org/10.1097/00006231-199903000-00004}}, doi = {{10.1097/00006231-199903000-00004}}, volume = {{20}}, year = {{1999}}, }